OMAHA, Neb., Oct. 2, 2024 /PRNewswire/ -- Ambetter from Nebraska Total Care, a product offered by a Centene Corporation (NYSE: CNC) company, which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, will offer Nebraskans a variety of affordable health insurance plans in plan year 2025. Open enrollment for the Health Insurance Marketplace for Nebraska runs from Nov. 1, 2024, through Jan. 15, 2025. Enroll by Dec. 15, 2024, for coverage starting Jan. 1, 2025.
"Ambetter from Nebraska Total Care provides critical health insurance coverage, allowing thousands of Nebraskans the peace of mind that they have the resources to take charge of their health," said Plan President and Chief Executive Officer of Nebraska Total Care, Adam Proctor. "Ambetter from Nebraska Total Care offers a variety of plan options to deliver cost-effective solutions to meet the health needs of each individual, while also providing a member experience that earns five out of five stars from the National Committee for Quality Assurance."
Ambetter from Nebraska Total Care offers its members access to quality care, convenient services and valuable rewards. The 2025 benefits and offerings include:
Ambetter from Nebraska Total Care or enrolling in a health plan during the open enrollment period may visit ambetterhealth.com/en/ne/.
About Ambetter from Nebraska Total Care
Ambetter from Nebraska Total Care serves under-insured and uninsured populations through the federal Health Insurance Marketplace®. Ambetter from Nebraska Total Care is underwritten by Nebraska Total Care, Inc., which is a Qualified Health Plan issuer in Nebraska. For more information, visit ambetterhealth.com/en/ne. This is a solicitation for insurance. For information on your right to receive an Ambetter from Nebraska Total Care plan free of discrimination, or your right to receive language, auditory and/or visual assistance services, please visit ambetterhealth.com/en/ and scroll to the bottom of the page.
Last Trade: | US$33.26 |
Daily Change: | -0.82 -2.41 |
Daily Volume: | 14,543,229 |
Market Cap: | US$16.330B |
July 29, 2025 July 25, 2025 April 25, 2025 February 24, 2025 |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load